Drug Price Trends for CANASA

Average Pharmacy Cost for CANASA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
CANASA 1,000 MG SUPPOSITORY	58914-0501-56	37.13662	EACH	2025-03-19
CANASA 1,000 MG SUPPOSITORY	58914-0501-56	37.13931	EACH	2025-02-19
CANASA 1,000 MG SUPPOSITORY	58914-0501-56	37.13931	EACH	2025-01-22

Market Analysis and Price Projections for CANASA (Mesalamine Suppository)

Overview of CANASA

CANASA, or mesalamine suppository, is a medication used for the treatment of mildly to moderately active ulcerative proctitis, a form of ulcerative rectal colitis. It is available in a 1000 mg strength and has been a significant player in the pharmaceutical suppositories market.

Market Size and Growth

The pharmaceutical suppositories market, which includes CANASA, has been experiencing strong growth. The global market size for pharmaceutical suppositories is projected to grow from $1.6 billion in 2023 to $1.7 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. By 2028, the market is expected to reach $2.19 billion with a CAGR of 6.5%[1].

Key Drivers of Growth

Several factors are driving the growth of the pharmaceutical suppositories market, including:

Increased Prevalence of Diseases

The rise in the prevalence of diseases such as ulcerative proctitis, kidney damage or failure, and hemorrhoids is a significant driver. For instance, the increased incidence of ulcerative proctitis directly impacts the demand for mesalamine suppositories like CANASA[1].

Product Innovation

Major players in the market are focusing on product innovation to enhance their market positions. The launch of generic versions of CANASA, such as the one by Teva Pharmaceuticals Inc. in April 2021, contributes to market growth by providing more affordable treatment options[1].

Government Initiatives and Regulatory Approvals

Government initiatives and new regulatory approvals for marketing suppositories also play a crucial role. For example, the FDA approval for the generic version of CANASA by Rising Pharmaceuticals in 2019 expanded the availability of this treatment[4].

Price Projections and Cost Considerations

Current Pricing

Mesalamine suppositories, such as CANASA, have significant market sales. For instance, the U.S. sales of mesalamine suppositories were approximately $263 million for the 12 months preceding the launch of Rising Pharmaceuticals' generic version in 2019[4].

Impact of Generic Versions

The introduction of generic versions of CANASA is expected to reduce prices. Generic drugs typically offer a more affordable alternative, which can lead to increased market penetration and higher sales volumes.

Regulatory and Policy Changes

The Biden-Harris Administration's initiatives to lower prescription drug prices, as part of the Inflation Reduction Act, may also impact the pricing of drugs like CANASA. While CANASA is not specifically listed among the drugs selected for Medicare price negotiation, broader policy changes aimed at reducing prescription drug costs could influence the market dynamics[5].

Competitive Landscape

Major Players

Companies like Teva Pharmaceuticals Inc. and Rising Pharmaceuticals are key players in the market. These companies are engaged in strategic partnerships, technological advancements, and product innovation to maintain their market share[1][4].

Market Segmentation

The market is segmented by type, bases, and end users. For example, in countries like Australia and Indonesia, the market is segmented by these criteria, indicating a diverse and competitive landscape[1].

Patient Convenience and Adherence

Focus on Patient Needs

The pharmaceutical suppositories market is also driven by a focus on patient convenience and adherence. Products like CANASA are designed to be easy to use and effective, which enhances patient compliance and overall market demand[1].

Key Takeaways

• The pharmaceutical suppositories market, including CANASA, is expected to grow significantly, driven by increased disease prevalence, product innovation, and government initiatives.
• The introduction of generic versions is likely to reduce prices and increase market penetration.
• Regulatory and policy changes aimed at lowering prescription drug costs may further impact the pricing and availability of CANASA.
• Major players are focusing on strategic partnerships, technological advancements, and patient convenience to maintain market share.

FAQs

What is CANASA used for?

CANASA, or mesalamine suppository, is used for the treatment of mildly to moderately active ulcerative proctitis, a form of ulcerative rectal colitis.

How is the market for pharmaceutical suppositories expected to grow?

The global market for pharmaceutical suppositories is expected to grow from $1.6 billion in 2023 to $2.19 billion by 2028 at a CAGR of 6.5%.

What are the key drivers of growth for the pharmaceutical suppositories market?

Key drivers include the rise in healthcare expenditure, new regulatory approvals, increased prevalence of diseases like ulcerative proctitis and hemorrhoids, and a focus on product innovation and patient convenience.

How do generic versions impact the market for CANASA?

Generic versions of CANASA reduce prices, making the treatment more affordable and increasing market penetration.

What regulatory changes might affect the pricing of CANASA?

Regulatory changes such as those introduced by the Inflation Reduction Act, aimed at reducing prescription drug costs, could influence the pricing and availability of drugs like CANASA.

Who are the major players in the pharmaceutical suppositories market?

Major players include Teva Pharmaceuticals Inc. and Rising Pharmaceuticals, among others.

Sources

1. Pharmaceutical Suppositories Global Market Report 2024 - ResearchAndMarkets
2. Recent and Forecasted Trends in Prescription Drug Spending - HealthSystemTracker
3. Canada Pharmaceutical Market Size & Share | Report, 2030 - GrandViewResearch
4. Rising Pharmaceuticals Announces the Launch of Mesalamine Suppository - BioSpace
5. Fact Sheet: Biden-Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation - The White House